The Analysis of Drug-Related Problems (DRPs) in the Therapy of Patients with Chronic Kidney Disease in the Inpatient Installation of X Hospital, Medan

Authors

  • Kukuh Putri Lestari Sekolah Tinggi Ilmu Farmasi Riau
  • Husnawati Husnawati Sekolah Tinggi Ilmu Farmasi Riau
  • Prasojo Pribadi Sekolah Tinggi Ilmu Farmasi Riau

DOI:

https://doi.org/10.31004/koloni.v5i2.975

Keywords:

Chronic Kidney Disease, Drug-Related Problems, Clinical Outcomes, Inpatients.

Abstract

Chronic kidney disease is a progressive disorder that is often accompanied by complications and requires complex therapy, thus increasing the risk of Drug Related Problems (DRPs). The occurrence of DRPs can affect Clinical Outcomes in patients undergoing hemodialysis. The purpose of this study was to analyze the occurrence of DRPs and its relationship to the Clinical Outcomes of patients with chronic kidney disease in the Inpatient Installation of X Medan Hospital for the period January - December 2025. The method used was a descriptive analytical observation with a retrospective cross-sectional design with medical record data. The study sample was 57 patients who met the inclusion criteria. Data analyzed included patient characteristics, drug use, DRPs occurrence based on the Pharmaceutical Network Europe (PCNE) classification, clinical outcomes including blood pressure, hemoglobin and creatinine. The results of the study showed that the majority of patients were male (56.1%), for the 46-65 age group 59.6%, the most commonly used oats were sodium bicarbonate (52.63%), furosemide (43.86%). The incidence of DRPs in 41 patients (71.9%), with indications not being treated (73.17%), and potential interactions (26.83%). The clinical outcomes of most patients had not reached the therapeutic targets, namely, blood pressure (61.4%), hemoglobin (60.7%), and creatinine (57.9%). The conclusion of this study indicates that the incidence of DRPs in patients with chronic kidney failure is still high, potentially affecting clinical outcomes. Therefore, it is necessary to optimize the role of clinical pharmacists in identifying and monitoring therapy to improve the success of patient therapy.

References

Angraini, D., & Putri, R. (2016). Retensi natrium dan komplikasi kardiovaskular pada pasien penyakit ginjal kronis. Jurnal Keperawatan Indonesia.

Azzahra, A., & Supadmi. (2024). Karakteristik pasien gagal ginjal kronis yang menjalani hemodialisis berdasarkan jenis kelamin dan usia. Jurnal Ilmiah Farmasi Indonesia.

Bertram G. Katzung. (2023). Basic and Clinical Pharmacology (15th ed.). McGraw-Hill Education.

Biagio R. Di Iorio. (2019). Metabolic acidosis in chronic kidney disease: Treatment with sodium bicarbonate and clinical outcomes. Clinical Kidney Journal.

Ciarambino, T., et al. (2022). Sex differences in acute kidney injury and progression to chronic kidney disease. Journal of Clinical Medicine.

Daulton Grube. (2022). Insulin therapy and severe hypoglycemia in patients with chronic kidney disease. Diabetes Research and Clinical Practice.

Deng, X., et al. (2025). Aging population and increasing prevalence of chronic kidney disease: A global perspective. Kidney International Reports.

Freya Waddington. (2020). Analgesic use in chronic kidney disease: Safety and efficacy of paracetamol. Nephrology Review.

Gonzalez, J. (2026). Simplified ceftriaxone dosing strategies in chronic kidney disease patients based on renal function. Clinical Therapeutics.

Hashmi, S. (2024). Anemia management in chronic kidney disease: Pathophysiology and current treatment strategies. International Journal of Nephrology.

Huang, Y., et al. (2019). Exercise, gender differences, and progression to end-stage renal disease. BMC Nephrology.

Ismail, A. (2024). Cardiovascular safety of ondansetron among hemodialysis patients. American Journal of Kidney Diseases.

Jayaningsih. (2021). Karakteristik pasien gagal ginjal kronis berdasarkan jenis kelamin di rumah sakit. Jurnal Farmasi Klinik Indonesia.

Jia, X., et al. (2024). Proton pump inhibitors and adverse kidney outcomes: A systematic review. Frontiers in Pharmacology.

John Alchin. (2022). Pain management in chronic kidney disease: The role of paracetamol. Journal of Pain Management.

Juwita, D., et al. (2022). Analisis Drug Related Problems (DRPs) pada pasien rawat inap dan peran apoteker klinis. Jurnal Farmasi Klinik Indonesia.

KDIGO. (2024). KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes.

Katzung, B. G. (2012). Basic and Clinical Pharmacology (12th ed.). McGraw-Hill.

Kusumiati, N., et al. (2024). Profil penggunaan antidiabetik pada pasien diabetes melitus dengan komplikasi penyakit ginjal kronis. Jurnal Ilmu Kefarmasian Indonesia.

Lu, Y., et al. (2026). Insulin therapy in advanced chronic kidney disease patients with diabetes mellitus. Diabetes Care.

Maharianingsih, N., et al. (2021). Penatalaksanaan hiperfosfatemia pada pasien penyakit ginjal kronis. Jurnal Farmasi Indonesia.

Mallamaci, F., & Tripepi, G. (2024). Metabolic changes and chronic kidney disease progression in older adults. Nephrology Dialysis Transplantation.

Melamed, M. L. (2020). Sodium bicarbonate treatment in patients with stage 3 and 4 chronic kidney disease. American Journal of Kidney Diseases.

Mubarok, A., & Fortuna, D. (2025). Dampak Drug Related Problems terhadap outcome terapi pasien rawat inap. Jurnal Farmasi dan Ilmu Kefarmasian Indonesia.

Nakoshima, K. (2021). Insulin resistance and mineral bone disorder in chronic kidney disease. Clinical Nephrology.

Pawana Sharma. (2011). ACE inhibitor and angiotensin receptor blocker therapy in chronic kidney disease. Nephrology Reviews.

Portolés, J., et al. (2021). Management of anemia in chronic kidney disease using erythropoiesis stimulating agents. Clinical Kidney Journal.

Riset Kesehatan Dasar (Riskesdas). (2018). Laporan Nasional Riskesdas 2018. Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia.

Siahaan, R., & Tobing, M. (2024). Gambaran prevalensi penyakit ginjal kronis di Indonesia berdasarkan usia dan jenis kelamin. Jurnal Kesehatan Masyarakat Indonesia.

Sunil Bhandari. (2016). Renin-angiotensin system blockade in chronic kidney disease: Clinical benefits and limitations. Kidney International.

Sui Wei. (2025). Long-term paracetamol use and liver injury risk in chronic kidney disease patients. Journal of Clinical Pharmacy and Therapeutics.

Teresa Obrero Sojo. (2026). Gut microbiota modulation and hyperphosphatemia management in chronic kidney disease. Nature Reviews Nephrology.

Thompson, J. (2022). Comparison of ondansetron, granisetron, and palonosetron in chronic kidney disease patients. Supportive Care in Cancer.

Wahyudi. (2026). Penggunaan terapi RAAS pada pasien penyakit ginjal kronis dan outcome klinis. Jurnal Farmasi Klinik Indonesia.

Wulandari, S. (2019). Penatalaksanaan hiperfosfatemia pada pasien gagal ginjal kronis dengan terapi kalsium karbonat. Jurnal Keperawatan Medikal Bedah.

Downloads

Published

29-06-2026

How to Cite

Lestari, K. P., Husnawati, H., & Pribadi, P. (2026). The Analysis of Drug-Related Problems (DRPs) in the Therapy of Patients with Chronic Kidney Disease in the Inpatient Installation of X Hospital, Medan. KOLONI, 5(2), 1275–1285. https://doi.org/10.31004/koloni.v5i2.975

Issue

Section

Articles